Search
Displaying 11–20 of 662 for “retinitis clinical trial”
-
Research News
Applied Genetic Technologies Corporation (AGTC), a leading developer of gene therapies, has reported the six-month follow-up data in all patients treated with its gene therapy for X-linked retinoschisis (XLRS) in its Phase I/II clinical trial.
-
Kiora Reports Vision Restoration in Phase 1/2 Clinical Trial for Photoswitch Therapy
Research NewsThe company’s molecule is designed to restore some vision to people with ultra-low or no vision caused by advanced retinitis pigmentosa and other retinal diseases.
-
AGTC’s XLRP Gene Therapy Performs Well in Extension of Phase 2 Clinical Trial
Research NewsThe three-month results support the planned launch of the company’s Phase 2/3 Vista trial
-
Foundation News
The partnership will formalize an ongoing commitment by both companies to accelerate the development of treatments and cures for retinal diseases, while prioritizing a patient-centric approach.
-
Research News
The company is also planning to conduct the clinical trial at sites in the EU.
-
SparingVision Receives Authorization to Launch US Clinical Trial for its Cone-Preserving Treatment
Research NewsThe emerging therapy is designed to work independent of the mutated gene causing retinitis pigmentosa
-
ARVO 2019: Gene Therapy Clinical Trial for RP Caused by RLBP1 Mutations Ongoing in Sweden
Research NewsIn a Novartis lab study, mice with RLBP1 mutations had improved dark adaptation after receiving the gene therapy. The treatment remained effective after one year.
-
ProQR Receives FDA Authorization to Launch Clinical Trial for USH2A Therapy
Research NewsProQR, a biotech in the Netherlands developing therapies for rare diseases, has received authorization from the US Food and Drug Administration to launch a Phase I/II clinical trial for QR-421a, its treatment targeting mutations in exon 13 of the USH2A gene.
-
Phase 3 Clinical Trial of NAC Launched for RP Patients
Research NewsThe drug is thought to work independent of the mutated gene causing RP.
-
Pixium's PRIMA Bionic Vision System Restores Central Vision in Dry AMD Clinical Trial
Research NewsThe French bioelectronics company Pixium Vision has reported that its PRIMA bionic vision system has restored some central vision in patients with advanced dry age-related macular degeneration (AMD) participating in a clinical feasibility trial.
.png)
